Tagged with Cannabis,

Opinion Sophia Ononye outlines the history of cannabis as a medicine in the US and, following the first FDA approval of a cannabis-derived drug product in 2018, the highly promising landscape for further approvals.   The landscape for approved CBD products is highly promising and will undoubtedly lead to additional FDA…

Cannabis PharmaBoardroom’s new InFocus section examines the fast-growing and lucrative global medical cannabis market, touching on investment opportunities, regulatory hurdles, regional hotspots and more.   With cannabis and cannabinoid treatments increasingly accepted as legitimate and effective medicines for a wide variety of conditions from chronic pain to mental disorders and even…

Thailand Dr Tares Krassanairawiwong, secretary-general of the Thai FDA shares the recent reforms carried out in the hope of facilitating greater patient access to both domestic and internationally-produced treatments. Dr Krassanairawiwong also highlights the institution’s current priorities, including medical cannabis, positioning Thailand as a clinical trials hub, and further developing the…

Cannabis GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019, demonstrating that cannabinoid-based medicines can be highly profitable and potentially blazing a trail for other pharmaceutical companies to follow.   With more and more countries moving to legalise medical cannabis and…

Europe Dentons Germany’s Peter Homberg outlines the key requirements that companies need to fulfil in order to import medical cannabis into Germany and how attitudes and legislation on the topic are shifting across Europe.   In order to import medicinal cannabis from another country to Germany, like many other countries, the…

Medical Cannabis Thailand has recently gained a new status as the first Asian country to legalise medical cannabis for medical treatment and research. In a sweeping move, the Thai parliament voted unanimously in favor of its legalisation in November 2018, with the bill then signed into law in early 2019.    Starting…

Cannabis Five of the key emerging trends in the booming global medical cannabis and cannabinoid medicine industries.   Increasing Acceptance The reappearance of cannabis as a tool in our therapeutic toolbox comes at an important time when we have not witnessed any real advances in pharmacological pain management in decades Mark…

Canada A new white paper from Fasken law firm asserts that the early filing of patents for innovative products is crucial for companies hoping to succeed in the booming North American cannabis market   Canada’s decision to legalise cannabis for recreational use in 2018 is set to spur on the already…

USA David Bearman makes the historical case to be once again considered as a medicine across the USA, noting that economic – rather than health – concerns were behind the creation of the Marijuana Tax Act of 1937 and continue to persist to this day.   With all this history, why…

USA Monica Weldon looks at the history of medicinal CBD, its current usages in the USA, and why robust scientific research on its efficacy need to be conducted in order to ensure the safety of rare disease patients – many of them children – who are using CBD products for their…

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the progress that has been made over the past year in investments in medical cannabis and the outlook for 2019.     Due to ongoing research and studies, positive results are leading countries to reconsider the cannabis plant The cannabis industry…

Opinion In the light of several recent regulatory updates to Canada’s cannabis laws, lawyer Jean-Raphaël Champagne examines the potential for cannabis to be legalised for use in cosmetic products in Canada.   One thing that Bill C-51 did not change was the relationship between cannabis substances and cosmetic products in Canada…